Breaking News

WuXi to Open Offices in Boston and San Francisco

Broadens access to key biotech hubs

Related CONTENT

12.15.14

WuXi PharmaTech (Cayman) Inc. will open new offices in Boston and San Francisco in early 2015 aimed at providing greater access to companies in these biotech hubs as well as investment opportunities. In October, the company opened an office in Israel. WuXi also has U.S. facilities in St. Paul, Philadelphia, Atlanta, Plainsboro, NJ, and San Diego.

"Our vision is to enable anyone and any company to discover and develop healthcare products to benefit the world's patients," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "These new offices bring our comprehensive platform of integrated R&D services closer to where entrepreneurs are and where cutting-edge science is being done."

WuXi AppTec provides pharmaceutical discovery and development services, including lab testing, and API development and manufacturing.

Related Searches

Suggested For You

WuXi STA Completes Acquisition of BMS Manufacturing Facility

WuXi STA Completes Acquisition of BMS Manufacturing Facility

Metrion Biosciences Appoints Nick Foster as Chief Commercial Officer

Metrion Biosciences Appoints Nick Foster as Chief Commercial Officer

Vibalogics Advances Growth with Leadership Hires

Vibalogics Advances Growth with Leadership Hires

WuXi Biologics, WuXi STA Establish WuXi XDC JV

WuXi Biologics, WuXi STA Establish WuXi XDC JV

BioVaxys, Wuxi Biologics Enter Bioproduction Agreement

BioVaxys, Wuxi Biologics Enter Bioproduction Agreement

Executive Moves at Frontage

Executive Moves at Frontage

Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact

Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact

Softweb Solutions

Softweb Solutions

Vetio Animal Health

Vetio Animal Health

DCAT Week '17 Q&A: API Market Trends

WuXi AppTec Bioanalytical Service Unit Passes FDA Inspection

WuXi AppTec Bioanalytical Service Unit Passes FDA Inspection

STA Pharma Expands Changzhou Site

STA Pharma Expands Changzhou Site

WuXi AppTec Acquires HD Biosciences

WuXi AppTec Acquires HD Biosciences

WuXi AppTec Opens 3rd Biomanufacturing Center in PA

WuXi AppTec Opens 3rd Biomanufacturing Center in PA

Related Breaking News

Breaking News | Drug Development | Promotions & Moves

Boyds Adds Two Product Development Experts to Its Team

Welcomes Diane Shattock Ph.D., as director of product development & Ian Hollingsworth M.Sc. as associate director of product development.
10.19.21
Breaking News | Drug Development

Landmark Bio Appoints Two New Leaders to Executive Team

Welcomes Gregg Nyberg as chief technology officer and Michael Covington as chief quality and regulatory officer.
10.19.21
Breaking News | Collaborations & Alliances | Drug Development

Agenus Earns $20M BMS Milestone in Antibody Alliance

Doses the first patient in Phase I trial of AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody in cancer.
10.13.21
Breaking News | Collaborations & Alliances | Drug Development

Geneseeq, Zai Lab Enter Strategic Cancer R&D Alliance

Aims to advance Zai Lab's cancer drugs through partnerships in clinical trial recruitment, central lab testing, companion diagnostics and marketing.
10.13.21
Collaborations & Alliances | Drug Discovery

Eurofins DiscoverX Certifies KBI Biopharma

The companies will work together on critical components that can accelerate client-sponsored validation programs through downstream drug development.
10.11.21
Breaking News | Collaborations & Alliances | Drug Development

Pacira BioSciences to Acquire Flexion

Expands its leadership position in non-opioid pain management with Flexion’s lead product ZILRETTA.
10.11.21
Breaking News | Drug Development | Industry News

Supernus to Acquire Adamas Pharmaceuticals for $400M

Transaction provides two marketed products for Parkinson’s disease, GOCOVRI and Osmolex ER.
10.11.21
Breaking News | cGMP Manufacture | Drug Development | Industry News

Pace Analytical Acquires Velesco

Adds specialized CDMO services in liquid, semi-solid, and oral solid dose product development.
10.11.21
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development | Trials & Filings

AstraZeneca Submits EUA for LAAB Combo for COVID Prevention

Results from the PROVENT pre-exposure prophylaxis trial showed AZD7442 reduced the risk of developing symptomatic COVID-19 by 77%.
10.07.21
Breaking News | Drug Development | Industry News

AstraZeneca Acquires Caelum Biosciences

AstraZeneca will advance and accelerate ongoing Phase III development of CAEL-101, a potential first-in-class medicine for AL amyloidosis.
10.06.21
Bio News | Breaking News | Drug Discovery | Industry News

CN Bio Launches Oncology Service

Aims to improve cancer drug discovery approval rates.
10.05.21
Biologics, Proteins, Vaccines | Collaborations & Alliances | Drug Development

Compugen Earns $6M AstraZeneca Milestone in Antibody Alliance

First patient dosed in Phase 1/2 study of AZD2936 in advanced or metastatic non-small cell lung cancer.
10.04.21
Breaking News | Drug Development | Industry News

Merck, Ridgeback’s Molnupiravir Could Be First Oral Antiviral Pill for COVID

Reduced risk of hospitalization or death by 50 percent in patients with mild-to-moderate COVID-19, based on positive interim analysis of Phase 3 study.
10.01.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings

Roche’s Ronapreve Reduces Viral Load in COVID-19 Patients

Phase II/III trial met primary endpoint, showing Ronapreve significantly reduced viral load in patients hospitalized with COVID-19.
09.30.21
Breaking News | Drug Development | Industry News

RegeneRx Licensee Acquired by Korean Biopharma Group

GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharma and financial subsidiaries.
09.28.21